How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/moxifloxacin-isoniazid-rifampicin-pyrazinamide-ethambutol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol (Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-tuberculosis combination therapy. Area: Infectious Disease.

phase 3 Anti-tuberculosis combination therapy Multiple: DNA gyrase (moxifloxacin), mycobacterial cell wall synthesis (isoniazid, ethambutol), RNA polymerase (rifampicin), bacterial metabolism (pyrazinamide) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol (Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol) — Tuberculosis Research Centre, India. This is a fixed-dose combination of five anti-tuberculosis drugs that work synergistically to inhibit bacterial cell wall synthesis and protein production, killing Mycobacterium tuberculosis through multiple mechanisms.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol TARGET	Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol	Tuberculosis Research Centre, India	phase 3	Anti-tuberculosis combination therapy	Multiple: DNA gyrase (moxifloxacin), mycobacterial cell wall synthesis (isoniazid, ethambutol), RNA polymerase (rifampicin), bacterial metabolism (pyrazinamide)
INH, Rifampicin, Ethambutol and Pyrazinamide	INH, Rifampicin, Ethambutol and Pyrazinamide	All India Institute of Medical Sciences	phase 3	Anti-tuberculosis combination therapy	Multiple: mycolic acid synthesis (INH), bacterial RNA polymerase (Rifampicin), arabinosyl transferases (Ethambutol), bacterial energy metabolism (Pyrazinamide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-tuberculosis combination therapy class)

All India Institute of Medical Sciences · 1 drug in this class
Tuberculosis Research Centre, India · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol — Competitive Intelligence Brief. https://druglandscape.com/ci/moxifloxacin-isoniazid-rifampicin-pyrazinamide-ethambutol. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab